Register
Oral Anticoagulant Choice Matters in Bone Health, Says Study |
Journal Updates
eMediNexus Coverage from: 
Oral Anticoagulant Choice Matters in Bone Health, Says Study
eMediNexus,  22 October 2019
remove_red_eye 513 Views
#Cardiology #Orthopedics #Pharmacist

0 Read Comments                

Bone fractures are a risk to be considered when choosing the oral anticoagulant for a patient with non-valvular atrial fibrillation (Afib), suggests a study published online in the Journal of the American College of Cardiology.

The risk of poor osteoporotic outcomes was significantly lower with direct oral anticoagulant (DOAC) compared with vitamin K antagonist (VKA) therapy, as follows: Any fracture - 3.09% vs 3.77% (adjusted HR 0.85, 95% CI 0.74-0.97); Major osteoporotic fractures - 2.29% vs 2.82% (adjusted HR 0.85, 95% CI 0.72-0.99); Initiation of osteoporosis medication - 2.44% vs 3.14% (adjusted HR 0.82, 95% CI 0.71-0.95); Any fracture or starting osteoporosis medication - 5.21% vs 6.43% (adjusted HR 0.84, 95% CI 0.76-0.93).

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now